Friedreich ataxia (FRDA) is the most common inherited cause of ataxia.^[@R1]^ Optic neuropathy is a well-known but under-recognized clinical manifestation of FRDA.^[@R2][@R3][@R5]^ Although vision loss is initially mild,^[@R6][@R7][@R8]^ it becomes more prominent as the disease progresses, and there are numerous reports of patients who experience dramatic subacute vision loss similar to Leber hereditary optic neuropathy.^[@R9][@R10][@R11]^

Low-contrast letter acuity is a well-established clinical correlate of optic nerve disease across multiple neurologic disorders, and in FRDA, it has been found to be associated with predictors of disease severity such as age and GAA repeat length; non-neurologic measures of disease severity such as the presence of diabetes, hearing loss, and cardiomyopathy; and neurologic measures of disease severity such as the Friedreich ataxia rating scale, timed 9-hole peg test (9HPT), and timed 25-foot walk (T25W).^[@R12],[@R13]^ Because contrast acuity is easily and reliably measured, there is growing interest in its use as a clinical predictor of disease severity and surrogate outcome in clinical trials for FRDA, particularly among more affected patients.

However, the use of contrast acuity as a biomarker in FRDA is limited by a lack of longitudinal data. To determine the natural history of contrast acuity in these patients, we performed a longitudinal analysis of a large prospective cohort study of patients with FRDA. We hypothesized that contrast acuity would decrease linearly over time and that the rate of decrease would be greater for patients with longer GAA repeat lengths and earlier age at onset.

Methods {#s1}
=======

Standard protocol approvals, registration, and patient consents {#s1-1}
---------------------------------------------------------------

Institutional review board approval was obtained at each participating site, and written informed consent was obtained from all patients for participation in the study.

Study design {#s1-2}
------------

The Friedreich Ataxia--Clinical Outcome Measures Study (FA-COMS) is an ongoing prospective cohort study of patients with Friedreich ataxia being followed at one of 12 clinical sites since 2001.^[@R14][@R15][@R16]^ Baseline genetic confirmation was obtained via commercial or research testing, and information regarding age at onset and other medical comorbidities was collected. At each annual follow-up visit, participants underwent contrast letter acuity testing using retro-illuminated charts. High-contrast acuity was tested both monocularly and binocularly. Low-contrast acuity was tested binocularly using the 2.5% and 1.25% Low-Contrast Sloan Letter Charts at a distance of 2 m (Precision Vision, LaSalle, IL) using a protocol developed to measure visual dysfunction in MS and Friedreich ataxia,^[@R17]^ and the total number of letters correctly identified at each level of contrast was recorded. Visual acuity was measured by trained technicians, and participants wore their standard refractive correction for distance.

Statistical analysis {#s1-3}
--------------------

Statistical analyses were performed using STATA version 12 (College Station, TX). Multilevel linear regression models were used to model visual acuity at both high and low contrast as a function of time, with a random intercept and slope for each participant to account for intraindividual correlation of repeated measurements. Regression models were adjusted for diabetes using a time-varying covariate to capture both those who had diabetes at baseline and those who were diagnosed with diabetes during the follow-up period. Modification of the effect of time on visual acuity by GAA repeat length and age at onset was assessed using interaction terms. The duration of follow-up was highly variable, with many participants contributing only a single baseline visit and some contributing as many as 12 years of follow-up. To assess for potential information bias due to differential follow-up, linear regression models were constructed for the follow-up duration as a function of baseline demographic characteristics.

Results {#s2}
=======

At the time of this analysis, the FA-COMS cohort consisted of 764 patients, of whom 50.4% were female. The median age at onset was 11 years (interquartile range \[IQR\]: 7--17), with a median age at the baseline study visit of 23 years (IQR: 15--34). The smaller GAA allele had a median length of 666 repeats (IQR: 466--800), and the baseline prevalence of diabetes was 5%.

Of the 764 patients in the cohort, 332 participated in a single study visit and thus did not contribute data to the longitudinal analysis. The remaining 432 patients were followed up for a median of 5 visits over a median follow-up duration of 4.4 years (IQR: 2.0--6.3). At baseline, mean binocular visual acuity at 100% contrast was 58.8 letters (IQR: 55--65) of a maximum of 70, corresponding to a Snellen visual acuity equivalent of 20/20, but 7.6% of patients had 20/40 acuity or worse. This level of acuity generally qualifies as "visually impaired" and would limit the ability to drive without restrictions in almost all US states. At 2.5% contrast, the mean number of letters was 31 letters (95% CI: 25--42), and at 1.25%, it was 25 letters (95% CI: 14--33).

The mean difference in visual acuity between each follow-up visit and the baseline study visit at 100%, 2.5%, and 1.25% contrast ([figures 1--3](#F1 F2 F3){ref-type="fig"}), respectively, demonstrated a generally linear pattern of decrease, particularly at low contrast. In diabetes-adjusted multilevel regression models, the average rate of change in vision was −0.37 letters per year at 100% contrast (95% CI: −0.52 to −0.21), −0.81 letters per year at 2.5% contrast (95% CI: −0.99 to −0.65), and −1.12 letters per year at 1.25% contrast (−1.29 to −0.96). These estimates did not change after adjusting for sex, age at onset, or GAA repeat length. However, the addition of interaction terms did reveal a significant interaction between the GAA repeat length and time at low contrast but not high contrast. For each additional tertile of GAA triplet repeat, the number of letters lost per year increased by 0.26 letters (95% CI: 0.05--0.47) at 2.5% contrast and 0.21 letters (95% CI: 0.006--0.41) at 1.25% contrast. There was no significant interaction between the age at onset and time. Using these interaction terms, the predicted time to loss of 7 letters of contrast acuity stratified by tertiles of GAA repeat length and age at onset is shown in [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.
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Estimated number of years to loss of 7 letters of binocular 2.5% contrast acuity stratified by minimum GAA repeat length and age at onset
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Estimated number of years to loss of 7 letters of binocular 1.25% contrast acuity stratified by minimum GAA repeat length and age at onset
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At the final follow-up, mean binocular high-contrast acuity was 57.2 letters, again corresponding to a Snellen equivalent of 20/20. However, the percentage of patients who saw 20/40 or worse increased to 11.9%. Of the 65 patients who were seen at 9 follow-up visits, 11 (16.9%) saw 20/40 or worse, and of the 12 patients who were seen at all 11 follow-up visits, 4 (33.3%) saw 20/40 or worse.

Linear regression models were also constructed for the follow-up duration as a function of baseline demographic variables to assess for information bias due to differential follow-up. In univariate analyses, individuals with a history of hypertrophic cardiomyopathy at baseline had an average of 0.90 less years of follow-up than those without (95% CI: 0.37--1.42), and the follow-up duration decreased with increasing GAA repeat length (0.25 less years per quintile of higher GAA repeat length, 95% CI: 0.07--0.42). Otherwise, there was no association between age at onset, age at diagnosis, sex, diabetes, or scoliosis and follow-up duration.

Discussion {#s3}
==========

In this large prospective cohort study of patients with FRDA, there is a significant essentially linear decrease in low-contrast acuity over time that is greater in subjects with higher GAA repeat lengths. High-contrast acuity is also affected, but this becomes apparent only at longer follow-up intervals. This reduction in low-contrast acuity but sparing high-contrast acuity likely reflects subtle optic nerve dysfunction. Contrast sensitivity also relies on higher-order cortical visual integration, and recent studies have found evidence of cognitive impairment in FRDA including with visuospatial reasoning, so it is possible that this reduction in low-contrast acuity is multifactorial in etiology.^[@R18]^ However, cognitive impairment in FRDA is extremely mild and detectable only by detailed neuropsychological testing and thus is unlikely to affect contrast sensitivity. The fact that low-contrast acuity demonstrates a predictable decrease over time that depends on an internal predictor of disease severity (namely, GAA repeat length) supports its use as a potential biomarker in future studies. As a biomarker, low-contrast acuity has the advantage of being easily and reliably measured. This may be particularly relevant for gene therapy, in which treatment delivery remains a challenge, particularly for inherited CNS diseases. Development and validation of vision-based outcomes open the door to retinal gene therapy as a potential proof of concept in Friedreich ataxia and as a clinically relevant therapeutic intervention.

Despite being one of the largest cohorts of its kind, our study experienced sample size limitations, particularly at longer follow-up intervals. Although this was primarily due to censoring (and possibly mortality, given the association between hypertrophic cardiomyopathy and shorter follow-up duration) rather than loss to follow-up, this nevertheless introduces the potential for information bias. This becomes particularly relevant when calculating the time to loss of 7 letters, as our estimates of low-contrast acuity at 5--10 years are extrapolated from data collected primarily at 0--5 years. Furthermore, although 7 letters of low contrast represent 1 line of Snellen acuity equivalent and has been validated as a clinically meaningful outcome in MS and other patient populations because it is associated with detectable reductions in vision-related quality of life, it has not been specifically validated in Friedreich ataxia. The degree of low-contrast acuity loss is similar in Friedreich ataxia compared with MS,^[@R14]^ but this does not guarantee a similar reduction in vision-related quality of life because long-standing impairment may go unnoticed or be well compensated by early adaptive mechanisms. A recent survey of patients with FRDA and their families as part of a patient-focused drug development meeting identified vision loss as a concern, particularly when compounded on other sources of disability,^[@R19]^ and in this cohort, a notable proportion of the population had symptomatic vision loss defined as 20/40 or worse, especially later in the disease course. However, future studies of low-contrast acuity and vision-related quality of life are needed in Friedreich ataxia if it is to be used as a biomarker or surrogate outcome.
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